The Technical Signals Behind (AURA) That Institutions Follow
This article analyzes Aura Biosciences Inc. (NASDAQ: AURA) using AI models to provide technical signals for institutional trading strategies. Key findings include strong near and mid-term sentiment, resistance testing, and an exceptional risk-reward short setup. The report details position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis indicating support and resistance levels.
If You Invested $1,000 in Aura Biosciences, Inc. (AURA)
This article examines the historical performance of investing $1,000 in Aura Biosciences, Inc. (AURA) at various points in time. It details the company's focus on developing precision therapies for solid tumors, particularly its lead product candidate bel-sar for ocular oncology and bladder cancer, and highlights its clinical trials and regulatory designations. The report also provides financial data including market capitalization, current price, and EPS, along with year-by-year returns and comparisons to similar stocks.
More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k
Insiders at Aura Biosciences divested US$939k worth of stock over the last 12 months, with a significant portion occurring in the last quarter. While shareholders recently saw a 13% stock price increase, the consistent insider selling below the current price, coupled with low insider ownership (1.1%), suggests a need for vigilance. This activity raises questions about insiders' perception of the company's valuation and signals potential weakness, despite no insider buying in the past year.
More Money In The Bank For Aura Biosciences Insiders Who Divested US$939k
Insiders at Aura Biosciences divested US$939k worth of stock in the last year, with the largest single sale by Elisabet de los Pinos totaling US$241k. Although the stock recently increased by 13%, the insider selling activity, particularly at prices below the current valuation, raises questions about insiders' perceptions of the company's value. Insiders own only 1.1% of the company, and the lack of insider buying over the past year suggests caution may be warranted for potential investors.
Executive at Aura Biosciences (AURA) receives 14,858 RSUs
Conor Kilroy, an officer at Aura Biosciences, has received a grant of 14,858 restricted stock units (RSUs) as part of the company's 2021 Stock Option and Incentive Plan, at no cash cost. These RSUs will vest in two equal annual installments starting July 15, 2027, provided Kilroy remains in service. Following this transaction, Kilroy's direct holdings in Aura Biosciences common stock total 232,693 shares.
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com
This article announces the filing of Form DEF 14A by AURA BIOSCIENCES for June 29. It briefly highlights the company's stock performance, showing a 15.01% gain, and points readers to additional financial market data and tools available on Investing.com.
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com
This article reports on the filing of Form DEF 14A by AURA BIOSCIENCES for June 29. It briefly mentions the company's stock performance, showing a 3.20% increase, and includes various market data and other news headlines.
Aura Biosciences (NASDAQ: AURA) sets vote on 500M share authorization and equity plan tweak
Aura Biosciences is holding a virtual special stockholder meeting on August 5, 2026, to vote on two key proposals. These proposals include increasing the authorized common shares from 150 million to 500 million and amending the 2021 Stock Option and Incentive Plan to include pre-funded warrants in the calculation of annual share pool increases. The company states that these changes are necessary to provide flexibility for future capital raises, strategic transactions, and employee equity incentives.
Form DEF 14A AURA BIOSCIENCES For: 29 June By Investing.com
This article reports on the filing of Form DEF 14A by Aura Biosciences for the 29th of June. It briefly mentions that Aura Biosciences' stock (AURA) saw a 3.34% increase. The content primarily consists of financial market data and navigation links rather than detailed news.
Aura Biosciences Inc Actuals & Estimates (BOATS:AURA)
This article provides an overview of Aura Biosciences, Inc. (AURA) stock, including financial actuals and analyst estimates. It highlights the company's past earnings, revenue, and stock price performance, along with forecasts for future prices and upcoming earnings dates. The article also provides details on how to buy AURA stocks and its employee count.
Aura Biosciences Inc Actuals & Estimates (NASDAQ:AURA)
This article provides an overview of Aura Biosciences, Inc. (NASDAQ: AURA) stock, including its current price, market capitalization, analyst forecasts, and recent financial performance. It highlights that analysts predict a maximum price of $24.00 and a minimum of $15.00 for AURA, while the company's last reported earnings per share were -$0.50 against an estimate of -$0.40. The company is set to release its next earnings report on August 6, 2026.
AURA Forecast — Price Target — Prediction for 2027
This article provides a forecast for Aura Biosciences, Inc. (AURA) stock, including analyst price targets, past performance, and key financial metrics. It highlights that analysts have a maximum price estimate of $24.00 and a minimum of $15.00 for AURA, while the stock has shown a 4.27% increase over the last year. The company's market capitalization, upcoming earnings report date, and recent earnings per share are also detailed.
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones
This article provides an in-depth analysis of Aura Biosciences Inc. (AURA) stock, highlighting a current mid-channel oscillation pattern and divergent sentiment readings. It outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, identifying support and resistance levels across near-term, mid-term, and long-term horizons.
Precision Trading with Aura Biosciences Inc. (AURA) Risk Zones
This article from Stock Traders Daily provides a detailed analysis of Aura Biosciences Inc. (AURA), highlighting divergent sentiment readings and a mid-channel oscillation pattern. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones for different risk profiles. The analysis also includes multi-timeframe signal analysis, providing support, resistance, and signal strength for near-term, mid-term, and long-term horizons.
Aura Biosciences Inc (AURA) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Aura Biosciences Inc. (AURA) focusing on its dividend and stock split history. It indicates that AURA has distributed $0.00 in dividends over the past five years and lists no historical stock split data. The page also presents current stock performance and company information from TradingKey.
Aura Biosciences Inc (AURA) Institutional Confidence
This article provides details on the institutional confidence score for Aura Biosciences Inc. (AURA), alongside a list of its major institutional shareholders and their shareholdings. The data includes the number of shares held by firms like Frazier Life Sciences Management, Adage Capital Management, and BlackRock Institutional Trust Company. Aura Biosciences Inc. (AURA) shows a current share price of $6.315 with a slight increase.
Aura Biosciences (AURA) seeks charter increase to 500M shares; equity-plan tweak
Aura Biosciences is seeking shareholder approval to increase its authorized common shares from 150 million to 500 million and to amend its 2021 Stock Option and Incentive Plan. The proposed charter amendment aims to provide flexibility for future capital raising, acquisitions, and equity compensation, while the plan amendment will include pre-funded warrants in the annual share-count formula to ensure sufficient equity incentives. Shareholders are asked to vote on these proposals at a virtual Special Meeting on August 5, 2026.
Tax-related Aura Biosciences (AURA) insider sale covers RSU withholding
Aura Biosciences officer Anthony S. Gibney automatically sold 12,824 shares of common stock at $6.42 per share on June 16, 2026. This sale was conducted to cover tax withholding obligations arising from vested restricted stock units, and it was not a discretionary transaction. Following the sale, Gibney directly holds 265,354 shares of Aura Biosciences.
Aura Biosciences (AURA) files Form 144 to resell 37,500 RSU shares
Aura Biosciences (AURA) has filed a Form 144 to report a proposed resale of 37,500 shares of common stock. These shares are associated with a restricted stock unit (RSU) award granted under the company's 2021 Stock Option and Incentive Plan, dated June 2, 2025. The Form 144 itself does not signify a completed sale but rather an intent to sell, subject to vesting requirements.
Aura Biosciences (AURA) awards director RSUs and $6.21 stock options
Aura Biosciences director Antony C. Mattessich was granted 15,000 Restricted Stock Units (RSUs) and stock options for 30,000 shares at an exercise price of $6.21 per share on June 11, 2026. These equity awards were granted under the company's 2021 Stock Option and Incentive Plan and are subject to vesting on the earlier of June 11, 2027, or the next annual stockholder meeting, contingent on his continued service. Following these transactions, Mattessich directly holds 38,500 shares of Common Stock.
Aura Biosciences (AURA) director receives RSUs and stock options
Aura Biosciences (AURA) director David Michael Johnson received 15,000 Restricted Stock Units (RSUs) and stock options for 30,000 shares under the company's 2021 Stock Option and Incentive Plan. Both awards vest fully on the earlier of June 11, 2027, or the next annual stockholder meeting, contingent on his continued service. Following these grants, Johnson directly holds 194,167 common shares and 30,000 options, with additional indirect holdings through trusts and an LLC.
Aura Biosciences (NASDAQ: AURA) director receives RSUs and 30,000 stock options
Aura Biosciences director Sapna Srivastava received new equity awards comprising 15,000 restricted stock units (RSUs) and 30,000 stock options with an exercise price of $6.21 per share. These awards vest in full on the earlier of June 11, 2027, or the company’s next annual stockholder meeting, contingent on her continued service. Following the RSU grant, her total direct common stock holdings are 38,500 shares, in addition to the 30,000 stock options.
Aura Biosciences (AURA) director awarded 15,000 RSUs and 30,000 options
Aura Biosciences director Teresa Marie Bitetti received new equity awards comprising 15,000 restricted stock units (RSUs) and 30,000 stock options with an exercise price of $6.21 per share. These awards vest in full on the earlier of June 11, 2027, or the next annual stockholders' meeting, subject to her continuous service. Following this grant, Bitetti directly holds 36,000 shares of common stock in addition to the newly awarded options.
InvestingPro’s Fair Value spotted Aura Biosciences’ 47% decline By Investing.com
InvestingPro's Fair Value models accurately predicted a 47% decline in Aura Biosciences (NASDAQ:AURA) stock, which was identified as significantly overvalued in October 2024. The stock fell from $11.74 to $6.20, hitting the Fair Value target of $6.53 in March 2026. This case demonstrates the utility of InvestingPro's comprehensive valuation methodology in identifying overvalued stocks and helping investors avoid substantial losses.
Shareholders back Aura Biosciences (NASDAQ: AURA) directors and auditor
Aura Biosciences (NASDAQ: AURA) announced the results of its 2026 Annual Meeting of Stockholders. Shareholders elected David Johnson and Teresa Marie Bitetti as Class II directors to serve until the 2029 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting saw 52,784,744 shares represented out of 64,199,778 shares entitled to vote.
AURA Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for Aura Biosciences Inc (AURA), indicating a "Sell" consensus based on various technical indicators and moving averages. While some oscillators show "Buy" signals, several key metrics like MACD and most simple moving averages suggest a bearish outlook. The stock is currently trading above its 200-day simple moving average, though below several shorter-term moving averages.
Aura Biosciences completes phase 3 enrollment for eye cancer drug
Aura Biosciences announced the completion of enrollment for its Phase 3 CoMpass trial for belzupacap sarotalocan, a treatment for early choroidal melanoma, involving 108 patients. The company's stock has seen a significant 37% year-to-date surge, with topline data from the trial expected in the second half of 2027. Aura Biosciences, which holds more cash than debt, recently raised $299.4 million through a public offering and saw leadership changes with Natalie Holles appointed CEO.
Aura Biosciences completes enrollment in Phase 3 trial for early choroidal melanoma treatment
Aura Biosciences has completed enrollment for its Phase 3 CoMpass trial, which is evaluating belzupacap sarotalocan (bel-sar) as a potential first-line treatment for early choroidal melanoma. The trial, conducted with FDA Special Protocol Assessment, aims to deliver a vision-preserving option for patients. Topline results are anticipated in the latter half of 2027, which could lead to regulatory approval for this ocular oncology treatment.
Eye cancer trial hits 108 patients as Aura tests new frontline therapy
Aura Biosciences has completed enrollment of 108 patients in its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar), a frontline therapy for early choroidal melanoma. Topline data for the 15-month primary endpoint is anticipated in the second half of 2027. This pivotal trial, conducted under an FDA Special Protocol Assessment, positions bel-sar as a potential vision-preserving treatment for this eye cancer.
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Aura Biosciences has completed enrollment of 108 patients in its Phase 3 CoMpass trial for belzupacap sarotalocan (bel-sar) as a frontline treatment for early choroidal melanoma. Topline data for the primary endpoint are expected in the second half of 2027. Bel-sar aims to be the first approved vision-preserving therapy for this condition, addressing a significant unmet medical need.
AURA News | AURA BIOSCIENCES INC (NASDAQ:AURA)
This article provides recent news and analysis for AURA Biosciences Inc. (NASDAQ: AURA). Key updates include the completion of enrollment in the Phase 3 CoMpass trial for bel-sar in early choroidal melanoma, recent inducement grants under Nasdaq Listing Rule 5635(c)(4), and upcoming investor conference participations. The current stock price of AURA is also reported.
AURA: Bel-sar leads innovation in ocular oncology with robust data and a strong financial runway
AURA's Bel-sar treatment for early choroidal melanoma shows strong efficacy and safety, with Phase III data anticipated in 2027. The company is financially stable, supporting ongoing trials and potential pipeline expansion into choroidal metastases and ocular surface cancers. This information is based on insights from Aura Biosciences, Inc.'s 7th Annual Oncology Innovation Summit.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences, Inc. announced inducement equity awards to its new Chief Executive Officer and President, Natalie Holles, on May 19, 2026. The awards include stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs), with vesting schedules tied to continued service and performance conditions. These grants were approved by the Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).
Press Release: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement grants to two new employees under Nasdaq Listing Rule 5635(c)(4). These grants, totaling 18,300 stock options, were approved by the Compensation Committee of Aura's Board of Directors and are an incentive for them to join the company. The options vest over four years, with a 12-month cliff.
Aura Biosciences grants inducement equity awards to new CEO Natalie Holles under Nasdaq rules.
Aura Biosciences has granted inducement equity awards, including stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs), to its new CEO and President, Natalie Holles. These awards were approved under Nasdaq Listing Rule 5635(c)(4) and are tied to Ms. Holles' continued service and performance milestones. The grants aim to incentivize Ms. Holles and support Aura's strategy to strengthen leadership as it advances its clinical-stage therapies for solid tumors.
Large equity awards granted to Aura Biosciences (AURA) director Natalie Holles
Aura Biosciences director and officer Natalie C. Holles received substantial equity awards, including 553,844 restricted stock units (RSUs), 600,118 performance RSUs, and a stock option for 2,169,103 shares, all structured as Inducement Awards. These awards are tied to multi-year vesting schedules and continued service with the company, with specific dates for vesting commencements and an exercise price of $7.3900 for the stock option. Following these grants, Holles directly owns 1,153,962 shares of common stock.
New Aura Biosciences CEO awarded options on 2.17M shares at $7.39
Aura Biosciences (NASDAQ: AURA) has granted inducement equity awards to its new CEO and President, Natalie Holles, consisting of stock options for 2,169,103 shares at an exercise price of $7.39, 600,118 RSUs, and 553,844 PRSUs. These awards are subject to multi-year time-based and, for PRSUs, performance-based vesting conditions. The grants were approved under Nasdaq Listing Rule 5635(c)(4) and align the CEO's compensation with long-term share performance, though they also introduce potential dilution.
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Aura Biosciences announced inducement equity awards for its new CEO and President, Natalie Holles, consisting of stock options, restricted stock units (RSUs), and performance-based RSUs (PRSUs). These awards, approved by the Board in accordance with Nasdaq rules, are tied to continuous service and, for PRSUs, achievement of performance conditions. The company is a clinical-stage biotechnology firm developing precision therapies for solid tumors.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, Inc. announced that its senior management team will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. Live webcasts and replays of the fireside chats will be available on the company's website. Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences Inc. announced its senior management will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. The company, a clinical-stage biotechnology firm, is developing precision therapies for solid tumors, with its lead candidate bel-sar (AU-011) in late-stage development for early choroidal melanoma. Webcasts of the fireside chats will be available on their investor relations website.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference and the TD Cowen 7th Annual Oncology Innovation Summit. Members of its senior management team will present at these events, with webcasts available on the company's website. The company is developing precision therapies for solid tumors, including its lead candidate bel-sar for choroidal melanoma and bladder cancer.
[SCHEDULE 13G] Aura Biosciences, Inc. Passive Investment Disclosure (>5%)
This SCHEDULE 13G filing indicates a passive investment disclosure for Aura Biosciences, Inc. by TCG Crossover entities and Chen Yu, collectively holding over 5% of the company's common stock. The filing details the beneficial ownership, voting, and dispositive powers of TCG Crossover GP II, TCG Crossover Fund II, TCG Crossover GP III, TCG Crossover Fund III, and Chen Yu. The reported ownership percentages are based on 96,255,907 shares of Common Stock outstanding as of May 5, 2026, and exclude shares subject to Pre-Funded Warrants due to beneficial ownership limitations.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced its senior management will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. The company will host fireside chats at both events, with live webcasts available for investors. Aura Biosciences is developing precision therapies for solid tumors, including bel-sar (AU-011) for choroidal melanoma and other oncology indications.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences, a clinical-stage biotechnology company, announced that members of its senior management team will participate in upcoming investor conferences. The company specializes in developing precision therapies for solid tumors aimed at preserving organ function. The announcement was made on May 12, 2026, and further details can be found on globenewswire.com.
Aura Biosciences to Participate in Upcoming Investor Conferences
Aura Biosciences will participate in two upcoming investor conferences: the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on May 19, 2026, and the TD Cowen 7th Annual Oncology Innovation Summit on May 27, 2026. Members of their senior management team will hold fireside chats at both events. The webcasts will be available on the company’s website.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences announced its Q1 2026 financial results and key business advancements, including progress in its Phase 3 CoMpass trial for early choroidal melanoma, which is expected to complete enrollment by mid-2026 and report topline data in H2 2027. The company also appointed Natalie Holles as its new CEO and strengthened its balance sheet with a $299 million equity financing, extending its cash runway into the second half of 2028. Additionally, Aura provided updates on its clinical trials for metastases to the choroid, ocular surface cancers, and bladder cancer, with early data expected throughout 2026.
Aura Biosciences raises $299M, tests vision-preserving eye cancer drug
Aura Biosciences announced its Q1 2026 financial results, highlighted by an oversubscribed equity offering that raised $280.8 million in net proceeds, extending its cash runway into the second half of 2028. The company is advancing its Phase 3 CoMpass trial for early choroidal melanoma, with enrollment expected to complete by mid-2026 and topline data anticipated in Q2 2027. Natalie Holles was also appointed as the new CEO and President.
Aura Biosciences (NASDAQ: AURA) details $299M raise, cash runway and Phase 3 plans
Aura Biosciences announced a net loss of $33.7 million for Q1 2026, alongside a successful oversubscribed $299 million equity financing which extended their cash runway into the second half of 2028. The company is advancing its Phase 3 CoMpass trial for early choroidal melanoma, with topline data expected in Q2 2027, and is also progressing other clinical programs in ocular and bladder cancers. Natalie Holles has been appointed as the new CEO and President, succeeding founder Elisabet de los Pinos.
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences announced its first-quarter 2026 financial results and business updates, highlighting significant progress in its clinical trials, particularly the Phase 3 CoMpass trial for early choroidal melanoma, which is nearing enrollment completion with topline data expected in mid-2027. The company also reported a strengthened financial position after an oversubscribed $299 million equity financing, extending its cash runway into the second half of 2028. Additionally, Natalie Holles was appointed as the new CEO and President.
Biotech Aura Biosciences to stream two May investor fireside chats
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company, announced its participation in two investor conferences in May 2026. The company will host fireside chats at the H.C. Wainwright BioConnect Conference and the TD Cowen Oncology Innovation Summit, with live webcasts and 90-day replays available on its investor website. This news led to a mild positive market reaction, with AURA gaining 1.13% on the day of the announcement, adding approximately $10 million to its market capitalization.
